Caris Life Sciences, Inc.
CAI
$16.96
$0.825.08%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -26.19% | 35.07% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -26.19% | 35.07% | |||
| Cost of Revenue | 6.74% | 1.12% | |||
| Gross Profit | -36.55% | 51.03% | |||
| SG&A Expenses | 0.19% | 12.13% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.14% | 11.01% | |||
| Operating Income | -94.03% | 170.85% | |||
| Income Before Tax | -100.79% | 236.92% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -100.62% | 236.92% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -100.62% | 236.92% | |||
| EBIT | -94.03% | 170.85% | |||
| EBITDA | -88.84% | 147.13% | |||
| EPS Basic | -100.62% | 236.89% | |||
| Normalized Basic EPS | -100.75% | 244.90% | |||
| EPS Diluted | -100.65% | 248.00% | |||
| Normalized Diluted EPS | -100.79% | 245.90% | |||
| Average Basic Shares Outstanding | 0.12% | 0.04% | |||
| Average Diluted Shares Outstanding | -4.57% | -0.38% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||